Day One Biopharmaceuticals (NASDAQ:DAWN) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Day One Biopharmaceuticals (NASDAQ:DAWN) posted its quarterly earnings results on Tuesday. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.04), FiscalAI reports. Day One Biopharmaceuticals had a negative return on equity of 32.05% and a negative net margin of 113.53%.The business had revenue of $53.72 million during the quarter, compared to analysts’ expectations of $49.81 million.

Here are the key takeaways from Day One Biopharmaceuticals’ conference call:

• OJEMDA commercial traction: 2025 net product revenue was $155.4M (up 172% YoY) with Q4 revenue of $52.8M and >4,600 prescriptions; management reiterated 2026 OJEMDA guidance of $225M–$250M.
• Three‑year FIREFLY‑1 data strengthen clinical case: company reports a 53% objective response rate, median response duration ~19.4 months, no new safety signals, and a median time‑to‑next‑treatment (TTNT) of 42.6 months versus a 16.6‑month PFS, which management says supports durable clinical benefit.
• Pipeline and BD progress: acquisition of Mersana closed in January to add Emi‑Le (early activity in adenoid cystic carcinoma) with an updated dataset planned for mid‑2026 and potential accelerated development, plus DAY301 early signals expected H2 2026.
• Concentration and timing risks remain: Day One is heavily dependent on OJEMDA as its primary revenue driver and future performance hinges on persistence, new patient starts, payer dynamics, and successful enrollment/readout of FIREFLY‑2 (top‑line mid‑2027); statements are forward‑looking and company‑presented.

Day One Biopharmaceuticals Stock Performance

Shares of NASDAQ:DAWN traded down $1.00 during trading hours on Wednesday, reaching $11.02. The stock had a trading volume of 2,033,873 shares, compared to its average volume of 2,447,963. Day One Biopharmaceuticals has a 1 year low of $5.64 and a 1 year high of $13.20. The firm’s 50 day moving average is $10.63 and its 200-day moving average is $8.74. The stock has a market capitalization of $1.13 billion, a price-to-earnings ratio of -7.26 and a beta of -1.26.

More Day One Biopharmaceuticals News

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Record revenue and reaffirmed 2026 outlook — Day One reported Q4 product revenue of ~$52.8M and full‑year 2025 net product revenue of $155.4M, beating consensus. Management reaffirmed 2026 U.S. net product revenue guidance of $225–$250M, which supports growth expectations. Press Release
• Positive Sentiment: Pipeline expansion via acquisition — The company completed the January acquisition of Mersana, adding Emi‑Le (Phase 1 for ACC) and expanding oncology pipeline optionality, a longer‑term positive for valuation if assets advance. Press Release
• Positive Sentiment: Wedbush raises price target — Wedbush bumped its PT from $29 to $30 and maintained an “outperform” call, implying meaningful upside versus current levels and giving bullish third‑party validation. Benzinga TickerReport
• Neutral Sentiment: Earnings materials and call transcripts available — Full Q4 slide deck and earnings‑call transcripts were posted (useful for digging into unit trends, OJEMDA uptake, and margin drivers). These provide detail but are not immediately price‑moving by themselves. Slide Deck Presentation
• Negative Sentiment: EPS miss and margins remain a concern — Reported EPS of ($0.21) missed the ($0.17) consensus and the company still shows negative net margin and ROE, fueling near‑term disappointment and selling pressure despite the revenue beat. MarketBeat
• Negative Sentiment: Mixed analyst reactions — While some firms raised targets, Needham cut its PT to $17 and HC Wainwright trimmed to $22 (both kept “buy”), reflecting differing views on near‑term profitability and risk; the cuts add downward pressure even as other shops remain constructive. Benzinga

Insider Activity

In related news, insider Michael Vasconcelles sold 2,728 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $31,644.80. Following the transaction, the insider owned 4,397 shares of the company’s stock, valued at $51,005.20. This represents a 38.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Adam Dubow sold 6,395 shares of the firm’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $74,182.00. Following the completion of the sale, the insider owned 72,694 shares in the company, valued at approximately $843,250.40. This represents a 8.09% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 36,461 shares of company stock valued at $422,948. Insiders own 6.20% of the company’s stock.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. raised its holdings in Day One Biopharmaceuticals by 26.5% during the fourth quarter. Invesco Ltd. now owns 123,994 shares of the company’s stock worth $1,156,000 after purchasing an additional 25,952 shares in the last quarter. Oracle Investment Management Inc. purchased a new position in shares of Day One Biopharmaceuticals in the 4th quarter valued at $932,000. XTX Topco Ltd raised its stake in Day One Biopharmaceuticals by 62.9% during the 4th quarter. XTX Topco Ltd now owns 128,440 shares of the company’s stock worth $1,197,000 after acquiring an additional 49,592 shares in the last quarter. VARCOV Co. purchased a new stake in Day One Biopharmaceuticals in the fourth quarter valued at $261,000. Finally, Vestal Point Capital LP boosted its stake in Day One Biopharmaceuticals by 94.4% in the fourth quarter. Vestal Point Capital LP now owns 5,200,000 shares of the company’s stock valued at $48,464,000 after acquiring an additional 2,525,000 shares in the last quarter. 87.95% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

DAWN has been the topic of several recent research reports. Zacks Research upgraded Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, January 26th. Needham & Company LLC lowered their price objective on Day One Biopharmaceuticals from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a report on Monday, December 29th. HC Wainwright reduced their price target on Day One Biopharmaceuticals from $25.00 to $22.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Piper Sandler boosted their price target on shares of Day One Biopharmaceuticals from $25.00 to $26.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $26.14.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.